Όλο το DSpace

Πλοήγηση Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ) ανά Συγγραφέα "Tabak, F."

Αποτελέσματα 1-3 από 3

    • Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta 

      Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)
      Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ...

    • Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis 

      Kabacam, G.; Dalekos, G. N.; Cakaloglu, Y.; Zachou, K.; Bock, T.; Erhardt, A.; Zeuzem, S.; Tabak, F.; Yalcin, K.; Bozdayi, A. M.; Dienes, H. P.; Bozkaya, H.; Manns, M.; Wedemeyer, H.; Yurdaydin, C. (2012)
      Background/aims: The safety and efficacy of interferons in advanced delta hepatitis have not been explored. The aim of this subanalysis of a multi-center clinical trial was to compare the efficacy and safety of 48 weeks ...

    • Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta 

      Kabaçam, G.; Wedemeyer, H.; Savaş, B.; Keskin, O.; Dalekos, G.; Tabak, F.; Idilman, R.; Erhardt, A.; Yalçin, K.; Bozdayi, M. A.; Bozkaya, H.; Manns, M.; Dienes, H.; Yurdaydin, C.; Berg, T.; Böcher, W.; Bohle, H.; Buggisch, P.; Cornberg, M.; Ers̈oz, G.; Feyerabend, S.; Hinrichsen, H.; Manok, M.; Häussinger, D.; Herzog, W.; Hofmann, W. P.; Plein, K.; Hardt, H.; Porst, H.; Mederacke, I.; Rigopoulou, E. I.; Sentürk, H.; Wagner, E. K. V. (2014)
      Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ...